

NOV 21 2003

OFFICIAL


FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO: Examiner Dwayne C. Jones
COMPANY: U. S. Patent Office, Group Art Unit 1614
FAX NO.: (703) 308-4556
FROM: Jeff Lloyd 
DATE: November 21, 2003

NUMBER OF PAGES (INCLUDING COVER SHEET): 27

MESSAGE:

Re: Serial No. 09/970,558
INJECTABLE COMPOSITION
Our Docket No.: NPB-100D5

Attached hereto is

1. Amendment Under 37 CFR §1.111

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

I hereby certify that this paper is being
facsimile transmitted to the Patent and
Trademark Office on: 21 NOVEMBER 2003

AMENDMENT UNDER 37 CFR §1.111
Patent Application
Docket No. NPB-100D5
Serial No. 09/970,558

RECEIVED
CENTRAL FAX CENTER

NOV 21 2003

Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

Examiner : Dwayne C. Jones
Art Unit : 1614
Applicant(s) : David Carver, Timothy Prout, Hernita Ewald, Robyn Elliott, Paul Hendreck
Serial No. : 09/970,558
Filed : October 4, 2001
For : Injectable Composition

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Sir:

In response to the latest Office Action in the application identified above, Applicants make the following amendment, remarks, and submissions:

In the Claims:

1. (original) A pharmaceutical paclitaxel composition comprising:
paclitaxel;
polyethoxylated castor oil; and
an acid; said composition being such that at least 96.6% of the paclitaxel potency is retained when the composition is stored at 40°C for seven days.
2. (original) The pharmaceutical paclitaxel composition of claim 1, further comprising ethanol.
3. (original) The pharmaceutical paclitaxel composition of claim 1, wherein said acid is an organic acid.